Leukaemia Section
Short Communication

del (5q) solely in Myelodysplastic syndrome

Nahid Shahmarvand, Robert S. Ohgami

Department of Pathology, Stanford University, Stanford, CA, USA;
ROhgami@stanfordhealthcare.org

Published in Atlas Database: October 2016
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/del5qSoleID1134.html
Printable original version: http://documents.irevues.inist.fr/bitstream/handle/2042/68531/10-2016-del5qSoleID1134.pdf
DOI: 10.4267/2042/68531

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Review on Myelodysplastic syndrome with isolated deletion of 5q

Keywords
Myelodysplastic syndrome; chromosome 5; deletion 5q

Clinics and pathology

Disease
Myelodysplastic syndrome (MDS) with isolated deletion of chromosome 5q is part of a group of clonal disorders in myeloid stem cells with ineffective hematopoiesis which is manifested by morphologic dysplasia in hematopoietic cells and single or bilineage cytopenia(s). It is the only MDS subtype defined cytogenetically in the World Health Organization classification system.

Phenotype/cell stem origin
Myeloid stem cell.

Epidemiology
MDS with isolated del(5q) is present in <5% of MDS cases (Mallo et al., 2011). It occurs more often in women than in men, male:female ratio 7:3, with a median age of diagnosis at 65 to 70 years.

Clinics
Patients suffering from MDS with isolated del(5q) present with a macrocytic anemia, normal or increased platelet count and absence of significant neutropenia in their peripheral blood. The incidence of bleeding and infections is therefore low in these patients because of the absence of significant neutropenia and thrombocytopenia.

Blood transfusion dependency is seen in patients with severe anemia at diagnosis but also can develop in other patients (Germing et al., 2012). According to the Revised International Prognostic Scoring System (IPSS-R), MDS with isolated del(5q) are defined as Low- or Intermediate -1- risk subtypes and usually have an indolent course.

Pathology
The bone marrow is characterized by an increase in the number of small megakaryocytes with monolobulated and bilobulated nuclei. There are less than 1% blasts in the peripheral blood and less than 5% blasts in the bone marrow and Auer Rods are absent (Arber et al., 2016).

Treatment
MDS patients with isolated del(5q) have a favorable prognosis and the majority of patients respond well to treatment with lenalidomide.
**Prognosis**

This subtype of MDS has a favorable prognosis. The exception is when this disease is associated with mutations in TP53.

**Cytogenetics**

**Cytogenetics morphological**

As its name implies, in this entity there is interstitial deletion of part of the long arm of chromosome 5 involving 5q31-5q33. MDS with isolated del(5q) can still be diagnosed if there is 1 additional cytogenetic abnormality besides del(5q) if there is no adverse effect of that abnormality, as such, this excludes {CC: TXT:monosomy 7 or del 7q} ID: for instance (Arber et al., 2016).

**Cytogenetics molecular**

The gene specific for the defect seen in MDS with isolated del(5q) has been identified by RNA interference screening to be RPS14 (Pellagatti et al., 2008). In addition, while patients with MDS with isolated del(5q) classically have a favorable prognosis, the presence of a TP53 mutation is of particular importance, this mutation predicts for poorer prognosis and higher risk of transformation to AML (Mallo et al., 2013).

**References**


**Genes involved and proteins**

**RPS14 (ribosomal protein S14)**

**Location** 5q33.1

**Protein**

RPS14 is a ribosomal gene located in commonly deleted region (CDR) of 5q. It encodes for a protein required for maturation of 40S ribosomal subunits. Patients with MDS with del(5q) are haploinsufficient for RPS14 which leads to impairment of ribosome biogenesis and subsequent reduction of protein translation.

**TP53 (Tumour protein p53 (Li-Fraumeni syndrome))**

**Location** 17p13.1

**Protein**

The TP53 gene encodes for the tumor suppressor protein p53. In the presence of DNA -damage p53 may be activated to fix the damage, or if the damage cannot be repaired p53 prevents the cell from dividing and signals the cell to undergo apoptosis.
del (5q) solely in Myelodysplastic syndrome

Shahmarvand N, Ohgami RS


This article should be referenced as such: Shahmarvand N, Ohgami RS. del (5q) solely in Myelodysplastic syndrome. Atlas Genet Cytogenet Oncol Haematol. 2017; 21(8):297-299.